Empagliflozin Reversal of Arterial StiffnEss in Aging

Inclusion Criteria: * Able to provide consent * 60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses) * Stable anti-hypertensive medication regimen (if in use) for at least 90 days * Evidence of arterial stiffening (defined as carotid-femoral PWV \>/= 8 m/s) at the time of screening visit. Exclusion Criteria: * Diabetes * BMI\>/= 45kg/m2 * Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke * Estimated glomerular filtration rate GFR \< 29 mL/min * Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin) * Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women) * Use of hormone replacement therapy * Body weight change ≥10% within the last 6 months * Uncontrolled hypertension during screening visit (\>180/110 mmHg) * Symptomatic hypotension and/or a SBP \<100 mmHg * History of ketoacidosis * High fall risk per assessment of study physician and/or safety officer at the time of screening (results must be abnormal for both fall risk assessments and orthostatic blood pressure measurements) * Anticipated need of prolonged fasting * History of recurrent UTIs or mycotic genital infections * Following a low-carbohydrate diet (\<20 grams/day) * Participation in regular exercise \> 3 days/week per week at a moderate or vigorous intensity * Known sensitivity to nitrate medications